UCB SA (UCB-BT)

QUOTE AND NEWS
GenEng News  Jul 17  Comment 
Amgen and UCB have acknowledged that their Biologics License Application (BLA) for Evenity™ (romosozumab) has been rejected by the FDA. The companies said yesterday that they received a Complete Response Letter asking them to include in...
Financial Times  May 22  Comment 
Drugmaker’s shares plunge on fears osteoporosis medication will not win approval
MarketWatch  May 22  Comment 
Amgen Inc. shares dropped 1.9% in morning trade Monday after the company said that it has observed new cardiovascular risks for its Evenity drug, which is intended to reduce risk of fractures in patients with osteoporosis, and that it does not...
FierceBiotech  May 22  Comment 
Amgen and UCB's romosozumab trounced a comparator drug in a trial in osteoporosis, but there's a big catch: The therapy seems to cause side effects that will delay and could scupper its chances of reaching the market.
GenEng News  May 22  Comment 
Amgen and UCB’s bone-forming antibody drug candidate Evenity™ (romosozumab) met primary and secondary endpoints in the Phase III ARCH study in postmenopausal women with osteoporosis at high risk of fracture. However, women treated using the...
MedPage Today  Mar 6  Comment 
(MedPage Today) -- Met primary efficacy goals versus placebo; third trial still to come





You may also be interested in articles related to UCB SA (UCB-BT):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki